Surmodics Inc (SRDX) 23.19 $SRDX Myriad Genetics Buys

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 12:24 PM

Surmodics Inc (SRDX) 23.19 $SRDX

Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26)

SurModics to Present at Jefferies Healthcare Conference
BusinessWire - Wed Jun 01, 7:05AM CDT
SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies Healthcare Conference in New York City on Tuesday, June 7, 2016, at 4 p.m. ET (3 p.m. CT).
SRDX: 23.19 (-0.11)

GNC Holdings Q1 Results Weak, Overseas Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:01AM CDT
GNC Holdings (GNC) made a disappointing start to its first quarter of 2016 with the results squarely missing the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), GNC: 25.65 (-0.52)

Thermo Fisher to Buy FEI, Boost Electron Microscopy Platform
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:58AM CDT
The FEI deal is expected to be accretive to Thermo Fisher's (TMO) adjusted EPS by 30 cents in the first full year after close.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), TMO: 151.80 (-2.35), BAX: 44.49 (-0.26), FEIC: 106.75 (-0.48)

IDEXX Laboratories: Strong Instrument Placement Drives Q1
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:12AM CDT
IDEXX (IDXX) started off 2016 on a strong note, with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), IDXX: 88.88 (-1.37)

Cepheid: GeneXpert Placements High, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:51AM CDT
Cepheid (CPHD) started 2016 on a promising note with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), CPHD: 28.27 (-0.60)

Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), QGEN: 21.71 (-0.49)

ResMed Posts Mixed Q3 Results, Brightree Buyout on Track
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:35AM CDT
ResMed (RMD) posted a lackluster third-quarter fiscal 2016. Nevertheless, ResMed's segmental as well as geographical performance was strong.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), RMD: 59.80 (-0.70)

ResMed: Positive CAT-HF Study Results to Drive ASV Sales
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:51AM CDT
The positive CAT-HF study results encourage us to expect a rise in demand for the wide range of products offered by ResMed (RMD) in the respiratory care market.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), RMD: 59.80 (-0.70)

Edwards Lifesciences: Q1 Strong, TAVR Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:50AM CDT
Edwards Lifesciences (EW) made a strong start to 2016, with its first-quarter results beating estimates on both the fronts.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), EW: 101.52 (-0.96)

Baxter Unveils THERANOVA Dialyser at ERA-EDTA Congress
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:42AM CDT
Baxter International Inc. (BAX) recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers.
SRDX: 23.19 (-0.11), IRMD: 21.35 (-0.13), MASI: 52.10 (-0.32), BAX: 44.49 (-0.26)

Baxter (BAX) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:22AM CDT
On May 20, Zacks Investment Research raised Baxter International Inc. (BAX) to a Zacks Rank #1 (Strong Buy).
SRDX: 23.19 (-0.11), MASI: 52.10 (-0.32), BAX: 44.49 (-0.26), EW: 101.52 (-0.96)

Quality Systems (QSII) Q4 Earnings Disappoint, Stock Falls
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:21AM CDT
Shares of Quality Systems Inc. (QSII) plunged almost 10% in after-hours trading following the company's disappointing fourth-quarter fiscal 2016 results.
SRDX: 23.19 (-0.11), MASI: 52.10 (-0.32), EW: 101.52 (-0.96), QSII: 12.44 (+0.08)

Boston Scientific's Full-Body MRI SCS System Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:20AM CDT
Boston Scientific's (BSX) Precision Montage MRI SCS allows patients to undergo a full-body 1.5 Tesla MRI scan while also delivering multiple waveforms.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), LMAT: 15.03 (-0.06)

Masimo (MASI) Scales a 52-Week High on Strong Q1 Results
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:16AM CDT
Shares of Masimo Corp (MASI) scaled a new 52-week high of $48.87 on May 18, eventually closing a tad bit lower at $48.51.
SRDX: 23.19 (-0.11), IRMD: 21.35 (-0.13), MASI: 52.10 (-0.32), EW: 101.52 (-0.96)

STERIS (STE) Misses on Q4 Earnings, Higher Tax a Concern
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:32AM CDT
STERIS (STE) ended fiscal 2016 on a disappointing note, with its fourth-quarter results missing the Zacks Consensus Estimate on both the fronts
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), STE: 70.74 (-0.93), BAX: 44.49 (-0.26)

Strong Q4 for PetMed (PETS), New Order & Reorder Sales Gain
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:19AM CDT
On May 13, 2016, we issued an updated research report on PetMed Express (PETS).
SRDX: 23.19 (-0.11), MASI: 52.10 (-0.32), PETS: 18.80 (-0.08), EW: 101.52 (-0.96)

Bristol-Myers' Opdivo Wins FDA Nod for Additional Indication
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:26AM CDT
Bristol-Myers' (BMY) Opdivo was approved for the treatment of patients with classical Hodgkin lymphoma (cHL).
SRDX: 23.19 (-0.11), ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08)

Edwards Lifesciences Presents Positive Data on Sapien3
Zacks Equity Research - Zacks Investment Research - Wed May 18, 7:20AM CDT
Results from this study demonstrated a survival rate of 98.1% at the end of 30 days, for patients implanted with a Sapien 3 valve from Edwards Lifesciences (EW).
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), BAX: 44.49 (-0.26), EW: 101.52 (-0.96)

Myriad Genetics Brings myVectra Web Portal for RA Patients
Zacks Equity Research - Zacks Investment Research - Tue May 17, 7:04AM CDT
Myriad's (MYGN) myVectra portal will offer easy access for its users to their Vectra DA test score, which in turn would keep the concerned RA patients better informed about the current status of their disease.
BSX: 23.02 (-0.30), SRDX: 23.19 (-0.11), MYGN: 30.95 (-3.07), BAX: 44.49 (-0.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ceipal Ora: AI Revolution for Staffing Firms Begins

Staffing Game Changer: Enter Ceipal Ora Folks in the staffing arena, hold onto your hats—Ceipal's rolling out something that could turn the tables. This new AI hotshot, Ceipal Ora, claims to be not just another AI patch on an old coat but the whole new garment itself. It's not just some afterthought glued to a platform; it's the glue holding the operations together,...

Trimble's New Machine Control Tech Promises Big Gains

Trimble's Latest Tech: A Game-Changer? The release of Trimble's MP1087 isn't just another upgrade—it's a leap forward. The folks over at Trimble decided to do some housekeeping with their machine positioning offerings, ditching separate components for a new all-in-one device. This bad boy doesn’t just promise—it delivers up to a 15% bump in uptime, even when...

Villas of Distinction Shines: Bags 11th Gold Travvy

Claiming Top Spot Repeatedly Another year, another accolade—Villas of Distinction has clutched its 11th Gold Travvy Award for "Best Villa Rental Company – Overall." This accolade ain't no small potatoes, as it's a testament to the company's unwavering excellence recognized by travel advisors worldwide. These folks, who have their fingers on the pulse of the industry,...

A Gentle Stake: Colts Neck's Rural Fight Ahead

Michael Fazio's Gambit in Colts Neck If you're not fired up about land deals, you should be now. Michael Fazio, the owner of Synergy Stables in Colts Neck, New Jersey, is laying his cards on the table with a proposition for preserving the integrity of the township's rural landscape. Rather than cashing in on monstrous offers for high-density housing, Fazio's plan involves...

When to Restore or Replace Hardwood Floors: Insights

The Challenge of Decision-Making with Old Hardwood Listen up, folks. You know that feeling when you're eyeballing that scuffed-up hardwood floor, pondering if you're looking at a lost cause? Well, before you lift a finger or pull out a crowbar, maybe tune into what Nick Hopkins from Hopkins Floor Company has got to say in HelloNation's latest piece. He breaks it down,...

Sokolove Law Wins $28.8M Verdict for Misdiagnosis Case

Jury Awards $28.8 Million in Misdiagnosis Case Well, here's a tale that's bound to ruffle some feathers in the medical community—$28.8 million tossed on the table because an emergency room missed a life-threatening aortic aneurysm. For the uninitiated, this isn't just chump change; it's the cost of dropping the ball when the stakes are as high as a human life. A jury in...

Navigating Simultaneous Home Buy and Sell Strategies

Juggling Two Housing Transactions You ever tried juggling chainsaws? That's what buying and selling your home at the same time can feel like. Selling First: Playing It Safe Some folks swear by selling their current home first, and there's good reason. It locks in your financial windfall, giving you a clear picture of your down payment and affordability. No more guessing...

Mesh Security Bolsters Team with Five Cybersecurity Experts

New Blood in Cybersecurity: Mesh's Strategic Moves Ever felt like the cybersecurity world is in a constant game of catch-up? You're not wrong. In today's digital battleground, companies don't just need more tools—they need collective wisdom to bind it all together. And it seems like Mesh Security just caught onto that notion, stacking their deck with five new...

Lauri Thompson Joins UWSN Board: A New Era Begins

Fresh Faces and New Perspectives In a move that merges legal acumen with community heart, Lauri S. Thompson of Greenberg Traurig has stepped up as a board member for the United Way of Southern Nevada (UWSN). Now, why should we care about this? Because when someone with Thompson's clout and eight-arm octopus of involvement links up with a nonprofit, things get interesting....

Historic Ted Williams Baseball Goes Up for Auction

When they say history's for sale, I guess they weren't kidding, were they? Here's a gem from the annals of baseball that might just light up your investment senses—the first Ted Williams-signed baseball from his early days with the Boston Red Sox in 1937 is up for auction. If you're a collector, or even just a baseball romantic, this one's hard to ignore. A Piece of...